Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Headquartered in Boston, Massachusetts, the company engineers "off-the-shelf" cell therapies with chimeric antigen receptors (CARs) to facilitate durable immune responses. Its distinctive approach leverages gamma delta T cells to target specific disease indications without requiring patient-specific cell harvesting.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
—
—
—
24,990
Gross Profit
—
—
—
24,990
Selling, General & Administrative Expenses
22,987
28,292
26,533
26,295
Research & Development Expenses
99,127
99,323
106,043
71,246
Other Operating Expenses
—
—
19,462
—
Operating Profit
(122,114)
(127,615)
(152,038)
(72,551)
Interest and Investment Income
5,777
10,714
9,978
3,760
Interest Expense
(36)
(4)
(25)
(80)
Non-Operating Income
(430)
(217)
(573)
(919)
Total Non-Operating Income
5,311
10,493
9,380
2,761
Income Before Provision for Income Taxes
(116,803)
(117,122)
(142,658)
(69,790)
Consolidated Net Income
(116,803)
(117,122)
(142,658)
(69,790)
Net Income Attributable to Common Shareholders
(116,803)
(117,122)
(142,658)
(69,790)
Basic EPS
-16.95
-21.33
-52.96
-27.20
Diluted EPS
-16.95
-21.33
-52.96
-27.20
Basic Weighted Average Shares Outstanding
6,891
5,492
2,690
2,568
Diluted Weighted Average Shares Outstanding
6,891
5,492
2,690
2,568
Shares Outstanding
9,587
5,161
2,704
2,685
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
38,918
56,495
159,711
257,656
Short-Term Investments
119,612
119,808
—
—
Total Cash and Cash Equivalents
158,530
176,303
159,711
257,656
Other Current Assets
2,396
3,833
2,561
3,382
Total Current Assets
160,926
180,136
162,272
261,038
Net Property, Plant & Equipment
28,481
36,752
44,201
48,979
Goodwill
—
—
—
19,462
Other Long-Term Assets
2,948
3,331
822
1,211
Total Assets
192,355
220,219
207,295
330,690
Accounts Payable
4,739
4,830
2,625
4,404
Accrued Expenses
13,606
11,430
13,441
12,811
Current Portion of Leases
3,186
3,132
3,221
2,492
Total Current Liabilities
21,531
19,392
19,287
19,707
Leases
11,552
14,102
17,703
18,531
Other Long-Term Liabilities
62
116
130
114
Total Long-Term Liabilities
11,614
14,218
17,833
18,645
Total Liabilities
33,145
33,610
37,120
38,352
Common Stock
10
5
4
4
Additional Paid-in Capital
773,795
684,482
550,943
530,448
Accumulated Other Comprehensive Income
102
16
—
—
Retained Earnings
(614,697)
(497,894)
(380,772)
(238,114)
Total Common Shareholders' Equity
159,210
186,609
170,175
292,338
Total Shareholders' Equity
159,210
186,609
170,175
292,338
Total Liabilities and Shareholders' Equity
192,355
220,219
207,295
330,690
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(116,803)
(117,122)
(142,658)
(69,790)
Depreciation & Amortization
6,381
6,468
6,098
2,575
Share-Based Compensation Expense
14,267
22,233
20,259
17,126
Other Adjustments
(564)
1,568
22,332
2,580
Changes in Accounts Payable
1,029
1,106
(1,683)
1,710
Changes in Accrued Expenses
1,904
(2,022)
750
5,831
Changes in Unearned Revenue
—
—
—
(4,805)
Changes in Other Operating Activities
(1,460)
(4,609)
1,185
8
Cash from Operating Activities
(95,246)
(92,378)
(93,717)
(44,765)
Capital Expenditure
(1,738)
(1,118)
(4,464)
(16,782)
Purchases of Investments
(140,869)
(129,124)
—
—
Proceeds from Sale of Investments
145,000
11,000
—
—
Cash from Investing Activities
2,393
(119,242)
(4,464)
(16,782)
Issuance of Common Shares
75,499
111,448
386
45,107
Repurchases of Common Shares
(104)
(141)
(150)
(3,234)
Net Issuance / (Repurchases) of Common Shares
75,395
111,307
236
41,873
Other Financing Activities
(150)
—
—
(364)
Cash from Financing Activities
75,245
111,307
236
41,509
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash